Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. - Document - Gale OneFile: Health and Medicine

PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Immunotherapy: an emerging modality to checkmate brain metastasis, Molecular Cancer

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study - The Lancet Oncology

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain